The Food and Drug Administration approved Foundation Medicine Inc.'s (Nasdaq: FMI) FoundationOne CDx diagnostic test for solid tumors sending the stock price soaring $9.40 to close at $62.60.
FDA approves Foundation Medicine's FoundationOne CDx
December 01, 2017 at 16:39 PM EST
